SCHEMBL14480968

SCHEMBL14480968

O=C1c2cc(-c3ccc(OC(F)(F)F)cc3)ccc2OCCN1CCN1CCOCC1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 2/20 0.67
SCN9A Q15858 2/20 0.67
SCN1A P35498 1/20 0.67
SCN4A P35499 1/20 0.67
KCNH2 Q12809 1/20 0.67
SCN2A Q99250 1/20 0.67
SCN3A Q9NY46 1/20 0.67
SCN8A Q9UQD0 1/20 0.67
SCN10A Q9Y5Y9 1/20 0.67
HRH3 Q9Y5N1 3/20 0.58
ABL1 P00519 5/20 0.49
ROCK2 O75116 2/20 0.49
ROCK1 Q13464 1/20 0.49
PRKDC P78527 2/20 0.43
EPHX2 P34913 4/20 0.42
BCR P11274 1/20 0.41
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14481344 0.94 HRH3 (0.67) SCN5ASCN9ASCN1ASCN4AKCNH2
SCHEMBL14480886 0.88 KCNH2 (0.69) SCN5ASCN9ASCN1ASCN4AKCNH2
SCHEMBL14480996 0.86 KCNH2 (0.65) SCN5ASCN9ASCN1ASCN4AKCNH2
SCHEMBL14480774 0.86 KCNH2 (0.67) SCN5ASCN9ASCN1ASCN4AKCNH2
SCHEMBL14480838 0.85 KCNH2 (0.71) SCN5ASCN9ASCN1ASCN4AKCNH2
SCHEMBL18290467 0.85 KCNH2 (0.71) SCN5ASCN9ASCN1ASCN4AKCNH2
SCHEMBL14552668 0.84 KCNH2 (0.65) SCN5ASCN9ASCN1ASCN4AKCNH2
SCHEMBL14480602 0.84 SCN1A (0.76) SCN5ASCN9ASCN1ASCN4AKCNH2
SCHEMBL14480960 0.83 KCNH2 (0.69) SCN5ASCN9ASCN1ASCN4AKCNH2
SCHEMBL14553943 0.83 KCNH2 (0.69) SCN5ASCN9ASCN1ASCN4AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3101013-B1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS GILEAD SCIENCES INC (US) 2020-10-21 EP disclosed
EP-3101013-B1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS GILEAD SCIENCES INC (US) 2020-10-21 EP disclosed
EP-3085694-B1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS GILEAD SCIENCES INC (US) 2020-03-25 EP disclosed
EP-3085696-B1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS GILEAD SCIENCES INC (US) 2020-03-04 EP disclosed
EP-3085696-B1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS GILEAD SCIENCES INC (US) 2020-03-04 EP disclosed
US-9676760-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2017-06-13 US disclosed
US-9676760-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2017-06-13 US disclosed
US-9676760-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2017-06-13 US disclosed
US-9598435-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2017-03-21 US disclosed
US-9598435-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2017-03-21 US disclosed
US-8586732-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-11-19 US disclosed
US-8586732-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-11-19 US disclosed
US-20130184255-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. (US) 2013-07-18 US disclosed
US-20130184255-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. (US) 2013-07-18 US disclosed
US-20130184255-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. (US) 2013-07-18 US disclosed
US-20130012492-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. 2013-01-10 US disclosed
WO-2013006485-A1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. (US) 2013-01-10 WO disclosed
WO-2013006485-A1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. (US) 2013-01-10 WO disclosed
US-20130012492-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. 2013-01-10 US disclosed
US-20130012492-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. 2013-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184255-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNJ4 SCN5A 47/4885SCN9A 95/4885SCN1A 64/4885
US-20130012492-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNJ4 SCN5A 47/4885SCN9A 95/4885SCN1A 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.